Results 81 to 90 of about 6,560 (205)

Structural analysis of the flexibility of the Ubl2 domain within the papain‐like protease of SARS‐CoV‐2

open access: yesActa Crystallographica Section F, Volume 82, Issue 6, Page 222-230, June 2026.
The ubiquitin‐like domain 2 (Ubl2) of the SARS‐CoV‐2 virus is necessary for the stability and catalytic efficiency of its papain‐like protease (PLpro). Our crystallographic study reveals that the Ubl2 domain exhibits notable flexibility and can adopt a conformation that places itself away from the PLpro catalytic domain, representing a new conformation
Gian Luca Freiherr von Scholley   +7 more
wiley   +1 more source

Fact sheet for Molnupiravir. Spanish

open access: yes, 2021
Title from PDF caption (viewed on January 4, 2022)."OHA4029C12292021 SPANISH"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program. It is for informational purposes and may

core  

Evolving to an Ideal Synthesis of Molnupiravir, an Investigational Treatment for COVID-19

open access: yes, 2020
Molnupiravir (MK-4482) is an investigational direct-acting antiviral agent that is under development for the treatment of COVID-19. Given the potential high demand for this compound, it was critical to develop a sustainable and efficient synthesis from ...
Tetsuji, Itoh   +18 more
core   +1 more source

PF‐07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID‐19 patients

open access: yesClinical and Translational Science, 2022
The ongoing pandemic of severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) and subsequently, coronavirus disease 2019 (COVID‐19), has led to the deaths of over 6.1 million people and sparked a greater interest in virology to expedite the ...
Raymond K. Hau   +2 more
doaj   +1 more source

Fact sheet for Molnupiravir. Portuguese

open access: yes, 2021
Title from PDF caption (viewed on January 4, 2022)."OHA4029C12292021 PORTUGUESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core  

The evolving role of structural biology in pharma: integration of X‐ray crystallography, cryo‐electron microscopy and beyond

open access: yesActa Crystallographica Section D, Volume 82, Issue 6, Page 587-602, June 2026.
This review describes how an integrated structural biology platform at Merck Sharp & Dohme LLC, Rahway, New Jersey, USA, combining X‐ray crystallography, cryo‐EM, MicroED and cryo‐ET, enables seamless three‐dimensional insights from molecular to cellular length scales.
Jill E. Chrencik   +44 more
wiley   +1 more source

Thorough QT/QTc Clinical Study to Evaluate the Effect of Remdesivir on Cardiac Repolarization in Healthy Participants

open access: yesClinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT QT interval prolongation associated with drug administration is an important consideration in drug development. Patients with COVID‐19 are at increased risk for cardiac complications, and QT interval prolongation correlates with higher mortality.
Chi‐Chi Peng   +6 more
wiley   +1 more source

Fact sheet for Molnupiravir. Chinese

open access: yes, 2021
Title from PDF caption (viewed on January 4, 2022)."OHA4029C12292021 SIMPLIFIED CHINESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core  

MOLNUPIRAVIR DAN NIRMATRELVIR/RITONAVIR SEBAGAI TERAPI ORAL COVID-19

open access: yes, 2022
COVID-19 merupakan penyakit infeksi yang disebabkan virus SARS-CoV-2 yang dideklarasikan sebagai pandemik global pada tanggal 11 Maret 2020. COVID-19 dapat berakibat fatal hingga menyebabkan kematian, sehingga diperlukan penanganan yang serius. Obat-obat
Raharjo, Sofyan Budi, Angelina, Emanuela
core   +1 more source

SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model

open access: yesNature Communications, 2022
Molnupiravir was the first orally available SARS-CoV-2 antiviral approved for outpatient use against SARS-CoV-2, but its efficacy against variants of concern, especially delta, was questioned.
Carolin M. Lieber   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy